DOCSLIB.ORG

The Real Deal on Synthetic Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Real Deal on Synthetic Drugs 2 presentations (part one) table of contents Community Drug Early Warning System: Recent Findings for Washington, DC 3 Bath Salts and Spice: Facts and Strategies 36 A Forensic Perspective on Synthetic Drug Trends 64 The Real Deal on Synthetic 3 Drugs: Recent Findings for Washington, DC July 17, 2014 Presented by: Eric D. Wish, Ph.D. Erin Artigiani, MA Center for Substance Abuse Research University of Maryland College Park www.cesar.umd.edu [email protected] 4 CESAR is… • Founded in 1990 as an interdisciplinary research center at the University of Maryland, College Park • Conducts policy-relevant research in all areas related to substance abuse • Maintains a clearinghouse of substance abuse information • Publishes the weekly CESAR Fax • Specializes in applied epidemiology 5 6 Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), December 2013. 2014* 13.0 2013 2012 2011 2010 2009 2008 2007 2006 7 2005 2004 2003 2002 2001 2000 District Columbia. forthe of Agency 1999 1998 Services 1997 Pretrial Pretrial June 2014 June 1996 - 1995 1994 1993 1992 1984 1991 1990 1989 1988 1987 1986 1985 1984 SOURCE: Adapted by from the by CESAR from data SOURCE: Adapted 0 Percentage of Washington, DC, Adult DC, of Washington, Percentage 20 10 40 30 60 50 70 Arrestees Testing Positive for Cocaine: Cocaine: for Positive Testing Arrestees Arrestees Testing Positive for Marijuana: for Positive Testing Arrestees 10 20 30 40 50 60 70 Percentage of Washington, DC, Juvenile Juvenile DC, of Washington, Percentage 0 1987 SOURCE: Adapted by from the by CESAR from data SOURCE: Adapted 1988 1989 1990 1991 1992 8 1993 1994 1987 1995 1996 1997 1998 - June 2014 June Pretrial Pretrial 1999 2000 Services Services 2001 2002 Agency District Columbia. forthe of Agency 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 38.8 2014 National Arrestee Drug Monitoring9 Programs • NIJ sponsored the development of the Drug Use Forecasting Program (DUF) in 1986 and the subsequent Arrestee Drug Abuse Monitoring Program (ADAM) in 2000 to track drug trends in 35 sites; Funding was eliminated in 2004 • ADAM II was re-established in 2007 by ONDCP • ADAM II is county specific and not statewide (N=4,412 male arrestees tested in 2 qtrs per yr) • In 2011, ADAM II operated in 10 sites; projected to be cut to 5 sites Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), December 2013. 10 CDEWS Goals • Assess the feasibility of the CDEWS methodology in different types of CJS populations and sites • Assess the value of expanding the drug testing protocol to include synthetic cannabinoids • Assess emerging drugs at the community level • Generate hypotheses and questions for future research Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), December 2013. 11 CDEWS Methodology CDEWS rapidly collects small random samples of CJS specimens that tested positive and negative and are ready to be discarded, without regard to age, gender, or charge Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), December 2013. 12 Location of Participating Study Sites 1 population in 3 populations in Prince George’s Washington, DC County, Maryland 1 population in Chesterfield, Virginia Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), September 2013. 13 Specimens Selected and Tested, by Site and Population CJS Test Result Subset Tested Site and Population Positive Negative Total for SC Washington, DC – Pretrial Services Agency for the District of Columbia Parole & Probation 197 103 300 156 Pretrial Surveillance 200 100 300 164 Lockup 200 100 300 162 Virginia – Chesterfield Community Corrections Services Probation 37 67 104 58 Maryland - Prince George’s County Drug Court Drug Court 16 44 60 51 Total 650 414 1064 591 Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), September 2013. The FRIENDS Laboratory Expanded Drug Screening Panel14 Drugs Tested, by Method Detection Limit Enzyme Immunoassay (EIA) Amphetamines 500 ng/mL Barbiturates 200 ng/mL Benzodiazepines 300 ng/mL Buprenorphine 5 ng/mL Cocaine 150 ng/mL MDMA 500 ng/mL Methadone 300 ng/mL Methadone Metabolite 300 ng/mL Opiates 300 ng/mL Oxycodone 100 ng/mL PCP 25 ng/mL THC 50 ng/mL Thin-layer Chromatography (TLC) Ami/Nortriptyline Hydroxyzine Amphetamines Methadone Ativan/Dalmane Morphine Benzodiazepines Oxycodone Clonazepam Opiates Cocaine Phenmetrazine Codeine Phenothiazines Demerol Quinine Dilaudid Tramadol Doxepin Valium Hydrocodone Confirmations Liquid Chromatography/Mass Spectrometry LC/MS was conducted on all EIA positives for opiates, amphetamines and buprenorphine. LC/MS confirmation for opiates was also conducted on all EIA oxycodone positives with a negative EIA opiate screen. Gas Chromatography/Mass Spectrometry GC/MS was conducted on all EIA positives for PCP. Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), September 2013. 15 SC Testing Panel for CDEWS 2 Synthetic Cannabinoid Metabolites Tested for in CDEWS 1 To be added in CDEWS 2 AM-2201 AKB-48 JWH-018 BB-22 JWH-019 PB-22 JWH-073 5F-AKB-48 JWH-081 5F-PB-22 JWH-122 AB-PINACA JWH-210 5F-AB-PINACA JWH-250 ADB-PINACA MAM-2201 ADBICA RCS-4 UR-144 XLR-11 Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), July 2014. Metabolites Found in All Synthetic Cannabinoid16 Positive Specimens from Five CJS Populations in Three Sites, 2013 (N=118) UR-144 and XLR-11 31% UR-144 Only 60% XLR-11 Only 4% UR-144 and JWH-018 3% 3+ Metabolites 2% Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), September 2013. Percentage of Specimens from Young Males17 Testing Positive for Synthetic Cannabinoids, by CJS Population and CJS Screen Result, 2013 (N=272 Specimens from Males ≤ Age 30) 50% 45% 39% 40% 37% 36% 35% 30% 28% 24% 25% 21% 19% 20% 20% % Positive 15% 13% 10% 5% NA 0% Pos Neg Pos Neg Pos Neg Pos Neg Pos Neg (N=60) (N=36) (N=39) (N=36) (N=25) (N=25) (N=16) (N=20) (N=0) (N=15) DC Parole & Probation DC Pretrial Surveillance DC Lockup Chesterfield Probation Prince George's County Drug Court CJS Population CJS Screen Positive CJS Screen Negative Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), September 2013. Percentage of Specimens from Three DC CJS Male18 Populations Combined Testing Positive for Synthetic Cannabinoids, by PSA Drug Screen Result and Age, 2013 (N=341 specimens from Washington, DC Parole & Probation, Pretrial Surveillance and Lockup) 100% 90% 80% 70% Percentage 60% Testing Positive for Synthetic 50% Cannabinoids 38%39% 40% 33% 31% 26% 30% 25% 22% 21% 17% 20% 10% 10% 7% 0% 0% 20 and Younger 21 to 25 26 to 30 31 to 40 41 to 50 51 and Older (N=28) (N=18) (N=40) (N=51) (N=56 (N=28) (N=23) (N=27) (N=23) (N=20) (N=15) (N=12) PSA Screen Positive PSA Screen Negative Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), September 2013. 19 Mean Age of Persons Positive for Specific Drugs (N=900 specimens collected from DC Lockup, Pretrial Surveillance, and Parole & Probation) Percent Positive by CDEWS Average Age Lab for: x ̅ (SD) Synthetic Cannabinoids (n=107) 28.5 (8.5) Marijuana (200) 31.0 (11.0) PCP (158) 34.5 (10.4) Oxymorphone (32) 39.9 (13.6) Hydrocodone (11) 40.0 (13.1) Hydromorphone (18) 40.2 (15.0) Oxycodone (30) 41.3 (13.5) Buprenorphine (72) 43.2 (13.5) Benzodiazepines (23) 43.3 (11.5) Opiates (152) 43.4 (12.7) Morphine (141) 44.1 (12.5) Codeine (127) 44.4 (12.3) Cocaine (170) 46.4 (10.2) Methadone (46) 50.2 (7.9) Source: Center Substance for Research Abuse (CESAR), Community Drug Early WarningSystem (CDEWS), September 2013. Other Drugs Found in Specimens Testing Positive by CDEWS20 Laboratory for Marijuana, Synthetic Cannabinoids (SC) or Both (N=210 specimens from Washington, DC Parole & Probation, Pretrial Surveillance and Lockup Populations Tested for Synthetic Cannabinoids) Marijuana Only Marijuana and SC Percent also Positive SC Only Positive by Positive by Positive by by CDEWS Lab for: CDEWS Lab CDEWS Lab CDEWS Lab (N=85) (N=103) (N=22) PCP 22% 23% 27% Marijuana 0 NA NA Cocaine 4 7 14 Codeine 8 7 5 Morphine 8 7 9 Buprenorphine 7 6 0 Oxymorphone 0 6 5 Oxycodone 0 5 5 Hydromorphone 1 1 5 Methadone 2 1 0 Benzodiazepines 0 1 0 Hydrocodone 1 1 5 Dextromethorphan 0 0 5 Tramadol 1 2 0 Synthetic Cannabinoids NA 0 NA Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), September 2013. NIDA Community Epidemiology 21 Workgroup • Our June 2014 was just submitted to NIDA • Covers Synthetics and other drugs • http://www.drugabuse.gov/ab out-nida/organization/ workgroups-interest-groups- consortia/community- epidemiology-work-group- cewg/meeting-reports/area- reports-june-2014 • CESAR will continue working with CEWG reps through NDEWS 22 What are Synthetic Cannabinoids? • A blend of herbs and plant material sprayed with one or more synthesized chemical compounds or metabolites that are believed to bind to the same receptors as THC • Sold in small pouches or packets of 0.5-10 grams each as herbal incense or potpourri and often marked as “not for human consumption” • Typically smoked in joints or pipes or ingested in tea • Can be more potent than marijuana • Not detected by standard drug tests • At least 41 states and Puerto Rico have passed legislation making synthetic cannabinoids illegal Source: Center for Substance Abuse Research (CESAR), December 2013.
Load more

Recommended publications
  • GHB, GBL & Related Compounds: Literature Review
    ACMD Advisory Council on the Misuse of Drugs An assessment of the harms of gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and closely related compounds November 2020 1 Contents 1. Introduction ................................................................................................................................... 4 2. Previous ACMD advice and legal status of GHBRS- UK ..................................................... 5 3. Chemistry and pharmacology ................................................................................................... 7 GHB ................................................................................................................................................... 7 GBL.................................................................................................................................................... 8 1,4-BD ............................................................................................................................................... 8 GHV/GVL .......................................................................................................................................... 9 4. Therapeutic and other legitimate uses of GHBRS ............................................................... 10 Therapeutic uses ........................................................................................................................... 10 Industrial/commercial uses .........................................................................................................
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Case: 1:18-Cr-00474-JRA; Zheng ECF Filed Indictment
    Case: 1:18-cr-00474-JRA Doc #: 1 Filed: 08/17/18 1 of 83. PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION UNITED STATES OF AMERICA, ) INDICTMENT Plaintiff, ~ JUDGE PO V. ~ CASE10; 18 CR ) Title 21, Sections 33l(a), FUJINO ZHENG, ) 333(b)(7), 35l(d), 841(a)(l), aka, GORDON JIN, ) (a)(2), (b)(l)(A), (b)(l)(C), (h), aka, MR. JIN, ) 843(c)(2)(A), 846, 848, 853, aka, GORDON ZHENG, ) 952(a), 959(a), 960(a)(l) and (3), aka, JINXINXIN, ) (b)(1 ), (b )(3), 963, and 970, aka, FU JING ZHENG, ) Title 18, Sections 1956(a)(2), (h), aka, DENG GAO, ) and 2, GUANGHUA ZHENG, ) United States Code aka, GUANG HUA ZHENG, ) ) Defendants. ) ) COUNT 1 (Conspiracy to Manufacture, Distribute, and Possess with the Intent to Distribute Controlled Substances and Controlled Substance Analogues Resulting in Death, 21 U.S.C. §§ 841(a)(l), (b)(l)(A), (b)(l)(C), all in violation of 21 U.S.C. § 846) The Grand Jury charges: 1. From on or about January 1, 2008 to the Present, the exact dates unknown to the Grand Jury, in the Northern District of Ohio, Eastern Division, the People's Republic of China, and elsewhere, Defendants FUJINO ZHENG, aka GORDON JIN, aka MR. JIN, aka GORDON ZHENG, aka JINXINXIN, aka FU JING ZHENG, aka DENG GAO; GUANGHUA ZHENG, aka GUANG HUA ZHENG; Guangfu Z.; Guifeng C.; Songyan J.; Longbao Z.; Qinghua Y., aka Jason Yen; Lynn X.; Leroy S.; (individuals whose names are known to the Grand Jury); Global United Biotechnology; Global United Holdings; Global Biotech, Inc.; Global Holdings, Inc.; Top Lab RC; Global RC; Golden Chemicals; Cambridge Chemicals; Wonda Science; OneChem; Case: 1:18-cr-00474-JRA Doc #: 1 Filed: 08/17/18 2 of 83.
    [Show full text]
  • Special Drug Groups 2
    Copyright Material – Provided by Taylor & Francis Special Drug Groups 2 Acetylcholinesterase Inhibitors While acetylcholinesterase inhibitors were historically used as pesticides and herbicides, in recent years they have been used to develop medica- tions to treat Alzheimer’s disease and myasthenia gravis. Commonly, their toxicity is measured by the percentage of acetylcholinesterase (ACh) activ- ity with toxicity beginning 20% below the level of normal activity (or 80% activity level) and becoming pronounced by 50% activity level. Severe tox- icity and death occur at 90% suppression (measured activity level = 10%). Postmortem testing should utilize the red blood cell (RBC), ACh as it better reflects neural ACh activity. Table 2.1 is a non-comprehensive list of common drugs, nerve agents, and insecticide/pesticides that are acetylcholinesterase inhibitors. 3 Copyright Material – Provided by Taylor & Francis 4 Table 2.1 Acetylcholinesterase Inhibitors Drugs—Alzheimer’s disease Drugs—myasthenia gravis Drugs—glaucoma Poisons—nerve agents Donepezil (Aricept) Ambenonium (Mytelase) Demecarium (Humorsol) Cyclosarin Galantamine (Razadyne, Reminyl, Edrophonium (Tensilon, Enlon, Echothiophate (Phospholine iodide) Sarin Nivalin) Reversol) Soman Medical for ExaminersHandbook Toxicology Forensic of Huperzine A Neostigmine (Prostigmin) Tabun Ladostigil Physostigmine (Antilirium) VX Metrifonate Pyridostigmine (Mestinon, VE Rivastigmine (Exelon) Regonol) VG Tacrine (Cognex) VM Insecticides or pesticides Acephate (Orthene) Dichlorvos (DDVP, Vapona) Formetanate
    [Show full text]
  • Addressing Synthetic and Designer Drugs in Adult Drug Courts By: Blaine Stum
    A Challenging Design: Addressing Synthetic and Designer Drugs in Adult Drug Courts By: Blaine Stum American University - Justice Programs Office is a technical assistance provider for the BJA Adult Drug Court Program. This fact sheet is part of a series created to respond to significant issues identified during the provision of technical assistance to the field. For more information about accessing technical assistance services or to learn more about the AU Justice Programs Office, go to www.american.edu/justice. Synthetic Drugs - Substances wherein the psychoactive properties of a scheduled drug have been retained, but the molecular structure has been altered in order to avoid prosecution under the Controlled Substances Act. - D.E. Smith and R.B. Seymour, 1985 Introduction Legal Status Over the last decade, the prevalence of synthetic and Currently, there are two laws that specifically address designer drugs has increased at alarming rates. The synthetic or designer drugs: European Monitoring Centre for Drugs and Addiction identified 13 new psychoactive substances (NPSs) in 1. The Federal Analogue Act (21 U.S.C. § 813) 2008 and 98 NPSs in 2015, a 653% increase in only 7 2. The Synthetic Drug Abuse Prevention Act (21 years.i A total of 480 NPSs were identified during U.S.C. 812(c)) that time frame. The Federal Analogue Act was passed by Congress in 1986. The bill amended the Controlled Substances Act (21 U.S.C. §801 et. Seq) so that synthetic or designer drugs that are “substantially similar” to drugs already on Schedule I or II are treated the same as those con- trolled substances.ii The Synthetic Drug Abuse Prevention Act was passed by Congress in 2012.
    [Show full text]
  • ENGR. SB NO. 12 Page 1 1 2 3 4 5 6 7 8 9 10 11
    1 ENGROSSED SENATE BILL NO. 12 By: Standridge of the Senate 2 and 3 Kannady of the House 4 5 6 An Act relating to Uniform Controlled Dangerous Substances Act; amending 63 O.S. 2011, Section 2-204, 7 as last amended by Section 1, Chapter 207, O.S.L. 2019 (63 O.S. Supp. 2020, Section 2-204), which 8 relates to Schedule I; modifying inclusions; and providing an effective date. 9 10 11 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: 12 SECTION 1. AMENDATORY 63 O.S. 2011, Section 2-204, as 13 last amended by Section 1, Chapter 207, O.S.L. 2019 (63 O.S. Supp. 14 2020, Section 2-204), is amended to read as follows: 15 Section 2-204. The controlled substances listed in this section 16 are included in Schedule I and include any material, compound, 17 mixture or preparation that contains any quantity of the following 18 hallucinogenic substances, their salts, isomers and salts of 19 isomers, unless specifically excepted, when the existence of these 20 salts, isomers and salts of isomers is possible within the specific 21 chemical designation. 22 A. Any of the following opiates, including their isomers, 23 esters, ethers, salts, and salts of isomers, esters, and ethers, 24 unless specifically excepted, when the existence of these isomers, ENGR. S. B. NO. 12 Page 1 1 esters, ethers, and salts is possible within the specific chemical 2 designation: 3 1. Acetylmethadol; 4 2. Allylprodine; 5 3. Alphacetylmethadol; 6 4. Alphameprodine; 7 5. Alphamethadol; 8 6.
    [Show full text]
  • 1 Councilmember Charles Allen 2 3 4 5 a BILL
    1 ___________________________ 2 Councilmember Charles Allen 3 4 5 6 A BILL 7 8 _____ 9 10 11 IN THE COUNCIL OF THE DISTRICT OF COLUMBIA 12 13 __________ 14 15 16 To amend, on an emergency basis, due to congressional review, the District of Columbia 17 Uniform Controlled Substances Act of 1981 to add certain classes and substances to the 18 list of Schedule I controlled substances. 19 20 BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this 21 act may be cited as the “Revised Synthetics Abatement and Full Enforcement Drug Control 22 Congressional Review Emergency Amendment Act of 2018”. 23 Sec. 2. The District of Columbia Uniform Controlled Substances Act of 1981, 24 effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-901.01 et seq.), is amended as 25 follows: 26 (a) Section 102(27) (D.C. Official Code § 48-901.02(27)) is amended as follows: 27 (1) Strike the phrase “as used in section 204(3) and section 206(1)(D)” and insert 28 the phrase “as used in section 204(3), (5), and (6) and section 206(1)(D)” in its place. 29 (2) Strike the phrase “As used in section 204(3)” and insert the phrase “As used in 30 section 204(3), (5), and (6)” in its place. 31 (b) Section 204 (D.C. Official Code § 48-902.04) is amended as follows: 32 (1) Paragraph (3) is amended as follows: 1 33 (A) The lead-in language is amended by striking the phrase “(for purposes 34 of this paragraph only, the term “isomer” includes the optical, position, and geometric isomers):” 35 and inserting a colon in its place.
    [Show full text]
  • New Psychoactive Substances (NPS)
    New Psychoactive Substances (NPS) LGC Quality Reference ISO 9001 ISO/IEC 17025 ISO Guide 34 materials GMP/GLP ISO 13485 2019 ISO/IEC 17043 Science for a safer world LGC offers the most extensive and up-to-date range of New LGC is a global leader in Psychoactive Substances (NPS) measurement standards, reference materials. reference materials, laboratory services and proficiency testing. With 2,600 professionals working When you make a decision using The challenge The LGC response We are the UK’s in 21 countries, our analytical our resources, you can be sure it’s designated National measurement and quality control based on precise, robust data. And New Psychoactive Substances In response to the ever-expanding LGC Standards provides the widest Measurement services are second-to-none. together, we’re creating fairer, safer, (NPS) continue to be identified, range of NPS being developed, LGC range of reference materials Institute for chemical more confident societies worldwide. and it appears that moves by the has produced a comprehensive available from any single supplier. and bioanalytical As a global leader, we provide the United Nations and by individual range of reference materials that We work closely with leading widest range of reference materials lgcstandards.com countries to control lists of meet the rapidly changing demands manufacturers to provide improved measurement. available from any single supplier. named NPS may be encouraging of the NPS landscape. Many of access to reference materials, the development of yet further these products are produced under with an increasingly large range variants to avoid these controls. the rigorous quality assurance of parameters, for laboratories standards set out in ISO Guide 34.
    [Show full text]
  • Free PDF Download
    European Review for Medical and Pharmacological Sciences 2019; 23: 9681-9690 New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard S. ZAAMI Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy Abstract. – OBJECTIVE: New psychoactive Introduction substances (NPS), are a range of drugs de- signed to mimic the effects of established illic- New psychoactive substances (NPS) are a it drugs, being legal at the time of their distribu- range of drugs that are designed, manufactured tion in illicit markets. The review aims to shed a light on the growing threat caused by NPS, and and marketed to replicate the effects of illegal on the dynamics and developments that have established substances (e.g., cannabis, cocaine, led to their spread, including the risk of new ecstasy and LSD1). At the time of their arrival adulteration practices which can cause a seri- on street and web markets, such substances are ous health threat, due to their increased toxicity, mostly not scheduled under the 1961 Single Con- e.g., through fentanyl and its analogs. vention on Narcotic Drugs or the 1971 Conven- MATERIALS AND METHODS: An overview of statistical trends relative to NPS use has been tion on Psychotropic Substances. Manufacturers provided, in addition to regulatory and legisla- of these drugs deliberately develop new chemi- tive approaches in several countries and recom- cals to replace others that have been banned. In mendations and data
    [Show full text]
  • Intoxication from the Novel Synthetic Cannabinoids AB-PINACA and ADB-PINACA: a Case Series and Review of the Literature
    Neuropharmacology xxx (2017) 1e10 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Invited review Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature * Patil Armenian a, , Michael Darracq a, Jirair Gevorkyan b, Shane Clark c, Bryan Kaye a, Nicklaus P. Brandehoff a a Department of Emergency Medicine, University of California, San Francisco-Fresno. 155 N Fresno St., Fresno, CA 93701, USA b Central Valley Toxicology, 1580 Tollhouse Rd, Clovis, CA 93611, USA c SkyLife Air Ambulance, 5526 E Aircorp Way, Fresno, CA 93727, USA article info abstract Article history: Synthetic cannabinoids (SC), are a novel class of designer drugs which emerged as a drug of abuse in the Received 23 June 2017 late 2000's. We report a case series of 6 patients who may have smoked a synthetic cannabinoid product Received in revised form in a remote wilderness setting. They presented with varying degrees of altered mental status, agitation, 22 September 2017 and seizures. Two were confirmed to have AB-PINACA, ADB-PINACA and their respective pentanoic acid Accepted 12 October 2017 metabolites in biological specimens via liquid chromatography time-of-flight mass spectrometry (LC- Available online xxx TOF/MS). Both compounds had DEA Schedule I classification at the time of case presentation, and 22 SCs are currently temporary or permanent DEA Schedule I. More than 150 SCs are known to date, and new Keywords: Synthetic cannabinoids compounds are appearing at a rapid rate on darknet and surface web e-commerce websites, marketed as “ ” “ ” Designer drugs research chemicals or legal highs.
    [Show full text]
  • Controlled Substances List (Adopted by Alabama State Board of Health on January 20, 2021, Effective January 20, 2021)
    1 Controlled Substances List (Adopted by Alabama State Board of Health on January 20, 2021, effective January 20, 2021) Schedule I (a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation (for purposes of 3-methylthiofentanyl only, the term isomer includes the optical and geometric isomers): (1) Acetyl-alpha-methylfentanyl (N-[1-[1-methyl-2-phenethyl]-4-piperidinyl]- N-phenylacetamide -------------------------------------------------------------------- 9815 (Federal Control Nov. 29, 1985; State Dec. 29, 1985) (2) Acetylmethadol ------------------------------------------------------------------------- 9601 (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl] benzamide -------------------------------------------------------------------------------- 9551 Federal Control May 16, 2016; State June 15, 2016 (4) Allylprodine ----------------------------------------------------------------------------- 9602 (5) Alphacetylmethadol --------------------------------------------------------------------- 9603 (6) Alphameprodine
    [Show full text]
  • STRANGER THAN FICTION: Modern Designer Drugs and the Federal Controlled Substances Analogue Act
    STRANGER THAN FICTION: Modern Designer Drugs and the Federal Controlled Substances Analogue Act Kathryn E. Brown∗ I.! INTRODUCTION Dylan McNabb was 19 years old when he murdered his grandmother.1 On the day of the murder, Dylan smoked a drug commonly known as “bath salts” and returned home to 78-year-old Imogene McNabb.2 Believing that she was possessed, Dylan picked up a shotgun and shot Imogene in the head, killing her.3 In an interview after the incident, Dylan reported that he believed she was the Antichrist and she intended to kill him.4 As of the time of this writing, he is in jail, awaiting trial for one count of first-degree murder.5 The stories stemming from bath salts use are truly stranger than fiction. After using bath salts, a 24-year-old Tennessee man jumped out of a third floor window to prove he was a god, and then got up and jumped off the second floor balcony on which he had landed.6 A Mississippi man attempted to skin himself alive;7 and a 19-year-old West Virginia man stabbed his neighbor’s pygmy goat while wearing women’s underwear.8 As ∗ J.D. Candidate, 2015, Sandra Day O’Connor College of Law at Arizona State University; B.A. Political Science, 2010, Arizona State University. I owe many thanks to Professor Gary Marchant, Julia Koestner, and Katherine May for their guidance, and my family for their support. Special thanks goes to my mother, Janet Gallup, for her unwavering encouragement. 1. Jonathan Gonzalez, Police: Grandmother Killer Possibly High on Bath Salts, BAKERSFIELDNOW.COM (Oct.
    [Show full text]